We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanoparticles for Anticancer Drug Delivery

By Biotechdaily staff writers
Posted on 05 May 2006
Two recent studies have described the use of nanoparticles to deliver chemotherapeutic drugs for the treatment of cancer.

Investigators at the University of Pennsylvania (Philadelphia, USA ) used polymersomes (artificial cells with degradable membranes made of polyethylene glycol polyester) as a means to deliver the anticancer drugs paclitaxel and doxorubicin. More...
Writing in the March 18, 2006, online edition of Molecular Pharamaceutics, they explained that when the polymer and the two drugs were mixed in an aqueous solution, polymersomes were generated that contained the water-insoluble paclitaxel embedded within the polyester shell, while doxorubicin, which is water-soluble, remained within the interior of the polymersome.

"The system provides a number of advantages over other Trojan horse-style drug delivery system, and should prove a useful tool in fighting a number of diseases,” said Dr. Dennis Discher, professor of engineering and applied science at the University of Pennsylvania. "Here we show that drug-delivering polymersomes will break down in the acidic environment of the cancer cells, allowing us to target these drugs within tumor cells.”

Investigators at the Massachusetts Institute of Technology (Boston, USA) also used a polyethylene glycol polymer to manufacture nanoparticles to transport the chemotherapeutic drug docetaxel into prostate cancer cells. The nanoparticles were targeted specifically for the tumor cells by incorporating RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells.

The nanoparticles were used to treat a group of mice that had been infected with human prostate cancers. Results published in the April 10, 2006, online edition of the Proceedings of the [U.S.] National Academy of Sciences revealed that a single injection of the nanoparticles completely eradicated the tumors in five of the seven treated animals, and the remaining animals also had significant tumor reduction, compared to the controls.



Related Links:
University of Pennsylvania
Massachusetts Institute of Technology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.